Antibiotice Statistics

Total Valuation

Antibiotice has a market cap or net worth of RON 1.41 billion. The enterprise value is 1.55 billion.

Market Cap	1.41B
Enterprise Value	1.55B

Important Dates

The next estimated earnings date is Thursday, April 10, 2025.

Earnings Date	Apr 10, 2025
Ex-Dividend Date	Sep 25, 2025

Share Statistics

Antibiotice has 671.34 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	671.34M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	1.04%
Float	117.94M

Valuation Ratios

The trailing PE ratio is 14.18.

PE Ratio	14.18
Forward PE	n/a
PS Ratio	2.05
PB Ratio	1.57
P/TBV Ratio	1.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	15.57
EV / Sales	2.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.08, with a Debt / Equity ratio of 0.16.

Current Ratio	2.08
Quick Ratio	1.32
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-366.54

Financial Efficiency

Return on equity (ROE) is 11.40% and return on invested capital (ROIC) is -106.62%.

Return on Equity (ROE)	11.40%
Return on Assets (ROA)	-86.04%
Return on Invested Capital (ROIC)	-106.62%
Return on Capital Employed (ROCE)	-158.44%
Revenue Per Employee	508,567
Profits Per Employee	73,643
Employee Count	1,350
Asset Turnover	0.57
Inventory Turnover	1.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.89% in the last 52 weeks. The beta is 0.09, so Antibiotice's price volatility has been lower than the market average.

Beta (5Y)	0.09
52-Week Price Change	+14.89%
50-Day Moving Average	2.37
200-Day Moving Average	2.79
Relative Strength Index (RSI)	22.24
Average Volume (20 Days)	247,750

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Antibiotice had revenue of RON 686.57 million and earned 99.42 million in profits. Earnings per share was 0.15.

Revenue	686.57M
Gross Profit	452.45M
Operating Income	-1.66B
Pretax Income	103.29M
Net Income	99.42M
EBITDA	-1.62B
EBIT	-1.66B
Earnings Per Share (EPS)	0.15

Full Income Statement

Balance Sheet

The company has 2.68 million in cash and 140.71 million in debt, giving a net cash position of -138.03 million or -0.21 per share.

Cash & Cash Equivalents	2.68M
Total Debt	140.71M
Net Cash	-138.03M
Net Cash Per Share	-0.21
Equity (Book Value)	897.61M
Book Value Per Share	1.34
Working Capital	246.07M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.90%, with operating and profit margins of -242.46% and 14.48%.

Gross Margin	65.90%
Operating Margin	-242.46%
Pretax Margin	15.05%
Profit Margin	14.48%
EBITDA Margin	-236.04%
EBIT Margin	-242.46%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 3.84%.

Dividend Per Share	0.08
Dividend Yield	3.84%
Dividend Growth (YoY)	-75.21%
Years of Dividend Growth	2
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	3.84%
Earnings Yield	7.05%
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.

Last Split Date	May 13, 2013
Split Type	Forward
Split Ratio	1.1819213313

Scores

Antibiotice has an Altman Z-Score of -0.25. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.25
Piotroski F-Score	n/a